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Abstract
Importance: Generic drugs play an essential role in the US healthcare system, providing less costly alternatives to
branded drugs that are equally effective and safe. The US Food and Drug Administration (FDA) regulatory policies
influence the standards for generic drug approval. In 2017, the FDA instituted several initiatives to promote generic
drug approval, particularly focused on those with limited competition.
Objective: To determine whether the initiatives begun by FDA in 2017 were associated with greater numbers of
approvals of generic drugs with limited generic competition and histories of drug shortage.
Study Sample and Design: We conducted a cross-sectional study of new drug applications (ANDA) approved by
FDA during two one-year periods: July 1st, 2016 to June 30th, 2017 (before the initiatives) and January 1st, 2018 to
December 31st, 2018 (after the initiatives). ANDAs were also characterized on the basis of their initial approval
year, priority review status and orphan designation status for the original new drug, World Health Organization
(WHO) essential medicine status, therapeutic area, drug complexity.
Main outcomes and measures: We determined (1) generic competition at the time of ANDA approval; (2) history
of drug shortage during the five years before ANDA approval.
Results: A total of 1,410 ANDAs were identified, 661 prior to the FDA’s initiatives, 749 afterwards. Overall, there
were 336 (23.8%) ANDAs originally approved with priority review status, 183 (13.0%) ANDAs previously
approved with orphan drugs status. 262 (18.6%) ANDAs were listed as essential medicine by WHO, and 265
(18.8%) generic approvals were categorized as complex generic drugs. In the pre-period, 234 (35.4%) of the
ANDAs approved were determined to have limited competition (≤3 ANDAs), as compared to 237 (31.6%)
afterwards (p=0.14). Similarly, 242 (36.6%) of the ANDAs approved in the pre-period had been in shortage during
the five years before ANDA approval, as compared to 282 (37.7%) afterwards (p=0.69). In multivariate analysis,
approval of generics with limited competition was significantly less likely during the period after the FDA’s
initiatives when compared to before (OR=0.76; 95% CI, 0.60-0.97; p=0.02), but there was no significant difference
in the approval of generics with histories of drug shortage (OR=1.09; 95% CI, 0.86-1.38; p=0.46).
Conclusion and relevance: The FDA’s initiatives in 2017 to promote generic drug approvals had limited impact on
the approval of ANDAs for drugs that lacked generic competition and had histories of drug shortage. Additional
efforts are needed to promote approval of generic drugs with limited competition.

Introduction
Generic drugs play an essential role in the US healthcare system, providing less costly alternatives to branded drugs
that are equally effective and safe. The 1984 Hatch-Waxman Act formalized the generic approval pathway, which
aims to limit patent terms of the brand-name drugs and promote generic approvals. Generic drugs accounted for
90% of total prescriptions in the United States in 20171. Despite this, there has been evidence that the generic drug
market was experiencing insufficient competition and long approval times, with a backlog of applications,
potentially limiting cost savings to patients and the healthcare system2,3. In response, Congress and the US Food and
Drug Administration (FDA) have continued to promote policies to foster generic drug approvals. 971 ANDAs were
approved or tentatively approved in FY 2018, up from 937 ANDAs in FY 2017 and 835 ANDAs in FY 20164.
As a marker of competition in the generic drug market, since 2016, the FDA has been tracking and publicly
reporting rates of first generic drug approvals5 , which is the first generic drug marketed, and therefore breaks the
monopoly of brand name drugs. Research has shown that 1 generic manufacturer only lowers the price of the brand
name drug by 13%, while significant savings are achieved only after 3-4 generic manufacturers are available on the
market6. Another study demonstrated high market competition level (at least 2 manufacturers) was associated with
price decrease over time7. This showed that the first generic approval alone, although symbols a good start, may not
be enough to achieve significant savings. Having multiple generic drug manufacturers is important not only for drug
prices, but also to prevent drug shortages. Previous research has shown that drug shortages are internally related to
the price increase and may result in disruptions in hospitals and pharmacies operation 2,8. In addition, research
suggested the number of manufacturers was associated with market status, and prioritizing approval of drugs with 3
or fewer generics were necessary9.
In 2017, the FDA established a series of initiatives to promote the approval and availability of generic drugs. First,
the agency successfully negotiated the authorization of GDUFA II with the pharmaceutical industry, which provided
the FDA with more financial resources to increase review capacity and commit to approval timelines. Secondly,
FDA Commissioner Scott Gottlieb introduced the Drug Competition Action Plan (DCAP) which explicitly
acknowledged the importance of approving drugs with less than three generics by prioritizing their review by the
agency when ANDAs are submitted10. Lastly, as a part of the FDA Reauthorization Act (FDARA), the FDA was
able to expedite the ANDA review process if there is only one approved drug in the active section of the Orange
Book11, which is a publication that identifies drug products approved by the FDA.

A recent Pew report evaluated FDA’s achievement during GDUFA I, and found that although approval numbers
increased during 2012-2017, the proportion of generic approvals with limited competition did not increase12. The
report also suggested that new initiatives in 2017 had more focus on drugs with limited competition. In order to
better understand the early impact of the FDA’s 2017 initiatives, this study characterized generic drug approvals by
the FDA during two one-year time period between 2016-2018. The objective of this study was to determine whether
the FDA’s efforts were associated with an increase in the number of generic drug approvals with limited generic
competition and that had previously been in shortage. Results from this study will inform future regulatory and
policy efforts to promote approval of generic drugs with limited competition.

Method
Sample construction
We used the Drugs@FDA database to identify all abbreviated new drug applications (ANDA) approved by FDA in
two one-year time periods: July 1st, 2016 to June 30th, 2017 (prior to FDA’s initiatives) and January 1st, 2018 to
December 31st, 2018 (after the FDA’s initiatives). We excluded all ANDAs approved between July 1st, 2017 and
December 31st, 2017 as a wash-out period to allow the FDA’s initiatives to take effect. We excluded tentative
approvals, biological treatments, over-the-counter products, and discontinued products.
Generic competition
Our primary outcome measure was the level of generic competition at the time of approval. For a specific generic
drug, we used the Drugs@FDA database to identify all drugs with the same active pharmaceutical ingredient and
dosage form of that drug. We then counted the number of ANDA approved at the time of approval for a generic
drug, excluding discontinued products, tentative approvals, and over-the-counter products. To determine the level of
generic competitions, we categorized ANDAs as having limited generic competition if there were 3 or fewer generic
drug manufacturers with FDA approved ANDAs at the time of the ANDA approval; ANDAs with 4 or more generic
drug manufacturers were not considered to have limited competition. This approach is consistent with the FDA
consideration, which was outlined in the Drug Competition Action Plan, that the FDA will expedite the review of
generic drug applications until there are three approved generics10.
History of drug shortage
Our second outcome measure was history of drug shortage during the five years before ANDA approval. We used
the University of Utah’s Drug Information Service drug shortage database. The database adopts the American

Society of Health-System Pharmacists (ASHP, http://www.ashp.org/ shortages) definition of shortage, which is
defined as a supply issue that affects how a pharmacy prepares or dispenses a drug product that influences patient
care when prescribers must use an alternative agent. The Drug Information Service receives voluntary reports of
drug shortages, which are confirmed by clinical pharmacists, who contact all manufacturers of a reported drug to
determine if there is a national shortage. A shortage is considered resolved when all manufacturers have all drug
products available, have discontinued their products, or the FDA reports on its website that the shortage has been
resolved.
For each drug in the sample, we searched for any shortage for the same active ingredient and dosage form in the
database that lasted longer than 1 month within the previous five years of the approval.
Covariates of Interest
Initial approval year
We determined the initial approval years for each drug in the sample. We used the Drugs@FDA database to search
for the first drug approved for the same active ingredient and dosage form. The year of approval for the first drug
was considered the initial approval year.
Priority review
We used the Drugs@FDA database to determine whether the initial new drug application for an ANDA received
priority review status. Priority review is granted to drug applications by the FDA and usually reflects that the new
drug presents significant improvements in the safety or effectiveness compared to standard treatments13. Upon
giving the status, the FDA will commit to complete the review in 6 months compared to the standard review time of
10 months.
Orphan drug status
Drug makers can seek their developing drugs to receive orphan designations from FDA, as long as the drugs
intended to treat diseases which affect less than 200,000 people in the US14. Orphan designation database is publicly
available15, and we used the database to determine whether the NDAs for a generic drug received orphan
designations. The orphan designation is based on indications, and one drug can receive multiple designations for
different indications. We consider the drug has orphan status in this study as long as the drug has a designation for
any indication.

WHO essential medicine status
WHO periodically publishes a list of Essential Medicine, which includes medicines that satisfy the priority health
care needs of the population16. The list is updated once every two years, and the most current version is published in
2017. Medicines on the list are fundamental and should always be available with the appropriate dosage forms,
adequate quantity, affordable price, and proper quality. We recorded drugs in our sample that are on the essential
medicine list, based on active ingredients.
Therapeutic area
Drugs in our sample were categorized based on the WHO Anatomical Therapeutic Chemical Classification System
(ATC code)17. We determined the therapeutic area based on the active ingredient and dosage form listed in the ATC
code system. To simplify categorization, we further grouped the ATC codes into eight therapeutic areas: alimentary
tract and metabolism, cardiovascular system, dermatologicals, genito-urinary system and sex hormones, infectious
disease, hematology-oncology, nervous system and sensory organs, others. If there is more than one ATC codes
correspond to one drug, we will refer to the initially approved indication for the active ingredient of that drug.
Complexity
We determined if the generic drug is considered a complex generic, based on a previous study3. The criteria include
whether a specific attribute make it difficult to manufacture the drug or establish bioequivalence, such as complex
active pharmaceutical ingredients such as peptide, polymer, naturally-derived complex mixtures, metal complex;
complex formulations such as liposomes, emulsions, gels; complex routes of delivery such as topical or ophthalmic;
complex dosage forms such as long-acting injectable or transdermal; complex drug-device combination such as
autoinjector. One author (KJ) independently reviewed each drug in the sample, and inconclusive drugs were
classified by another (RG).
Statistical Analysis
We used descriptive statistics to characterize the ANDAs approved by the FDA in both time periods, using χ2 tests
to determine if there were differences in the characteristics of the two samples. We then used the χ2 test to assess
whether there were differences in approval of ANDAs with limited generic competition and with a history of drug
shortage during the five years before ANDA approval before and after the FDA initiatives. Next, we conducted
independent nominal logistic regression analyses for each outcome measure as the binary dependent variable, time
period (before/after FDA initiatives) as the main independent variable, initial approval year (categorical), priority
review (binary), orphan drug status (binary), WHO essential medicine status (categorical), therapeutic area

(categorical), complexity (binary) as covariables. We reported odds ratios (OR) with 95% confidence intervals for
each of the parameters; all characteristics were kept in the model, because they were considered highly relevant to
the outcomes. All statistical tests were 2-sided and used a P value of 0.05 for significance. We created and cleaned
the sample with SAS 9.4 (SAS Institute Inc) and Excel 2019 (Microsoft Corp), and used JMP Pro 13 (SAS Institute
Inc) to conduct all the statistical analyses.

Result
During the 2 periods examined, a total of 1,410 ANDAs were approved by the FDA, covering 473 different active
ingredients (Table 1). There were 661 ANDA approvals during the 1-year period before the agency’s initiatives and
749 ANDA approvals during the 1-year period afterwards. Among these ANDAs, the most common original drug
initial approval year was 1995-2004, including 302 (45.8%) before agency initiatives and 299 (39.9%) afterwards.
Priority review for the original drug accounted for 135 (20.4%) ANDAs before agency initiatives and 201 (26.8%)
ANDAs afterwards. Orphan drug status was less common, with 62 (9.4%) ANDAs before agency initiatives and 121
(16.2%) ANDAs afterwards. Before the FDA’s initiatives, 111 (16.8%) were included in the WHO essential
medicine list, 151 (20.2%) afterwards. Drugs for nervous systems and sensory organs were most prevalent in both
the first time period (173 [26.2%]) and the second time period (151[20.2%]), followed by cardiovascular drugs
(102[15.4%] vs. 99[13.2%]) and infectious disease drugs (69[10.4%] vs. 111[14.8%]). Complex generic drugs
accounted for 118 (17.9%) ANDAs before the FDA initiatives and 147 (19.6%) ANDAs after the initiatives.
There were significant differences between the ANDAs approved before and after the FDA’s initiatives, as more
ANDAs were for drugs initially approved via priority review (p=0.005) and with an orphan designation (p<0.001)
after the FDA’s initiatives, and there were similarly changes in the therapeutic areas for which the drugs were
initially approved; there were no significant differences in initial approval year (p=0.17), WHO essential medicine
status (p=0.10) and drug complexity status (p=0.39).
Generic competition
Before the FDA’s initiatives, 234 (35.4%) of the ANDAs approved had limited competition (≤3 generics), compared
to 237 (31.6%) ANDAs afterwards (p=0.14) (Table 2). In multivariable analysis, controlling for priority review
status, orphan drug status, initial approval year, WHO essential medicine status, therapeutic area and drug
complexity, approvals for ANDAs with limited competition were significantly less likely after the FDA’s initiatives
when compared to before (OR=0.76; 95% CI, 0.60-0.97; p=0.02) (Table 3).

History of drug shortage
Before the FDA’s initiatives, 242 (36.6%) of the ANDAs approved had experienced a shortage in the previous five
years, compared to 282 (37.7%) afterwards (p=0.69) (Table 2). In multivariable analysis, there was no significant
difference in approvals for ANDAs with a prior history of drug shortage (OR=1.09; 95% CI, 0.86-1.38; p=0.46)
(Table 4).

Discussion
We conducted a cross-sectional study of 1,410 ANDAs approved before and after the FDA initiatives in 2017. Our
primary result indicated that ANDA approvals for drugs with limited competitions were less likely after the
initiatives, while no difference was found in approvals for drugs with prior drug shortage history. Our findings
suggest that the FDA’s initiatives, during the early period right after they went into effect, have not been effective in
promoting the approval of generic drugs with limited competition. The agency should continue to foster approvals
for generic drugs with limited competition, as well as generic drugs with prior shortage history.
Over the past 5 years, drug pricing has been the focus of significant public attention. High-profile incidents like
Turing Pharmaceuticals raising the price of Daraprim by over 50 times or Marathon hiking the price for Duchenne
Muscular Dystrophy drug provoked society’s thought about drug pricing and competition18,19. Adequate generic
competition is among the few ways to bring down drug prices and prevent “drug ventures” to raise drug prices
without reason. In response, prioritizing generic approval has been the center piece of the FDA’s agenda. Former
commissioner Scott Gottlieb has been vocal about promoting generic approvals 20. In addition, the Congress has also
provided important support, both through legislations like FDARA, which provided new tools to the agency such as
priority review and market exclusivity for drugs with limited competition, as well as bipartisan political support to
the FDA. It is crucial that the agency continue toward promoting approvals for drugs with limited generic
competition, especially since our study found that it was less likely for such drugs to receive approval in 2018. The
agency could increase transparency around the status of priority reviews, for example by publishing a list of generic
approvals that have received priority review from limited generic competition and disclosing number of applications
involved with limited generic competition monthly or quarterly.
At the same time, we also need to recognize that the drug approval is only one piece of the puzzle toward drug
availability. Recent report from Kaiser Family Foundation found 43% of the generics approved since 2017 were not
marketed till January 201921. This means the effect of generic drug approvals may be understated if few approvals

lead to an actually marketed and available generic drug as expected. Meanwhile, drug shortages also represent a
major influence in availability as its limited patient and physician choice of drugs, have ripple effect to put strain on
other manufacturers and even impact supply of substitution drugs. Market supply and demand should be the
foundation of economy, and drug shortages could mean market failure. It is therefore important for the FDA to take
actions, not only in notification system currently in place, but also looking into prioritizing approvals for drugs with
constant shortage issues. New manufacturers could bring in new supplier for active ingredients, new manufacturing
site for drugs, and at minimum companies that show interest in making the drugs. The agency could take previous
shortage history into consideration, and prioritizing reviews for those generics with the most shortage occurrences
and durations.
Limitations
This study has important limitations to consider. First, we only examined generic approvals, but many generic drugs
secure approval by the FDA but the ANDA sponsor does not bring the product to market after approval. We had no
data for the actual marketing status, so the impact of the approvals for limited competition generics was not well
understood. Second, while we focused on aspects of the generic drug market that have been explicitly mentioned by
the FDA as generic market factors that the agency’s initiatives would address, including competition level and
history of shortages, there are other aspects we did not examine, such as price.

Conclusion
In 2017, the FDA established a series of initiatives to promote the approval and availability of generic drugs,
particularly those with limited competition. Our analysis of the early impact of these initiatives found that they had
limited impact on the approval of ANDAs for drugs that lacked generic competition and had histories of drug
shortage, as approvals for generics with limited competition were actually less likely. Additional efforts are needed
to promote approval of generic drugs with limited competition.

Appendix
Table 1. Unadjusted associations between sample characterics and study timeframes

Sample Characteristic

7/2016 – 6/2017

1/2018 – 12/2018

(N/%)

(N/%)

Initial Approval Year

0.17

Before 1984

131 (19.8)

168 (22.4)

1984-1994

104 (15.6)

123 (16.4)

1995-2004

302 (45.8)

299 (39.9)

2005-2015

124 (18.8)

159 (21.2)

Priority Review

0.005

Standard

526 (79.6)

548 (73.1)

Priority

135 (20.4)

201 (26.8)

Orphan Drug Status

<0.001

Standard

599 (90.6)

628 (83.8)

Orphan

62 (9.4)

121 (16.2)

WHO Essential Medicine

0.10

No

550 (83.2)

598 (79.8)

Yes

111 (16.8)

151 (20.2)

Therapeutic Area

0.004

Alimentary tract and metabolism

54 (8.2)

73 (9.7)

Cardiovascular system

102 (15.4)

99 (13.2)

Dermatologicals

44 (6.7)

72 (9.6)

Genito-urinary system and sex hormones

63 (9.5)

54 (7.2)

Infectious disease

69 (10.4)

111 (14.8)

Hematology-oncology

69 (10.4)

96 (12.8)

Nervous system and sensory organs

173 (26.2)

151 (20.2)

Others

87 (13.2)

93 (12.4)

Complexity
Non-complex

P value

0.39
543 (82.2)

602 (80.4)

Complex

118 (17.9)

147 (19.6)

Table 2. Unadjusted associations between outcome measures and study timeframes
Sample Characteristic

7/2016 – 6/2017 (N/%)

1/2018 – 12/2018

P value

(N/%)
Generic Approvals at Launch

0.14

1-3 Approvals

234 (35.4)

237 (31.6)

>4 Approvals

427 (64.6)

512 (68.4)

Shortage within 5 years

0.69

No

419 (63.4)

467(62.4)

Yes

242 (36.6)

282 (37.7)

Table 3. Multivariable logistic regression model of sample characteristics associated with generics competition level

Sample Characteristic

OR (95% CI)

P value

Sample time period

0.76 (0.60,0.97)

0.02

Initial Approval Year
Before 1984

1.00

1984-1994

0.62 (0.42,0.94)

0.02

1995-2004

0.74 (0.54,1.03)

0.07

2005-2015

2.64 (1.85,3.77)

<0.001

Priority Review

0.88 (0.64,1.23)

0.47

Orphan Drug Status

1.24 (0.86,1.81)

0.24

WHO Essential Medicine

0.57 (0.40,0.81)

0.002

Therapeutic Area
Alimentary tract and metabolism

1.00

Cardiovascular system

0.81 (0.49,1.35)

0.42

Dermatologicals

1.30 (0.75,2.27)

0.35

Genito-urinary system and sex hormones

0.96 (0.55,1.67)

0.87

Infectious disease

1.35 (0.80,2.28)

0.26

Hematology-oncology

1.27 (0.76,2.14)

0.36

Nervous system and sensory organs

0.67 (0.42,1.07)

0.09

Others

0.88 (0.53,1.46)

0.62

Complexity

0.88 (0.65,1.19)

0.41

Table 4. Multivariable logistic regression model of sample characteristics associated with prior drug shortage history

Sample Characteristic

OR (95% CI)

P value

Sample time period

1.09 (0.86,1.38)

0.46

Initial Approval Year
Before 1984

1.00

1984-1994

0.83 (0.57,1.21)

0.33

1995-2004

0.51 (0.37,0.70)

<0.001

2005-2015

0.30 (0.20,0.44)

<0.001

Priority Review

1.06 (0.76,1.46)

0.73

Orphan Drug Status

1.14 (0.78,1.66)

0.51

WHO Essential Medicine

2.38 (1.71,3.33)

<0.001

Therapeutic Area
Alimentary tract and metabolism

1.00

Cardiovascular system

3.33 (1.94,5.73)

<0.001

Dermatologicals

0.51 (0.25,1.05)

0.07

Genito-urinary system and sex hormones

2.02 (1.10,3.71)

0.02

Infectious disease

2.88 (1.66,5.00)

<0.001

Hematology-oncology

3.01 (1.72,5.29)

<0.001

Nervous system and sensory organs

5.12 (3.07,8.54)

<0.001

Others

3.55 (2.05,6.13)

<0.001

Complexity

1.04 (0.77,1.39)

0.80

References
1.
IQVIA. Medicine Use and Spending in the U.S. April 19 2018.
2.

Chen SI, Fox ER, Hall MK, et al. Despite Federal Legislation, Shortages Of Drugs Used In Acute Care
Settings Remain Persistent And Prolonged. Health Aff (Millwood). 2016;35(5):798-804.

3.

Gupta R, Bollyky TJ, Cohen M, Ross JS, Kesselheim AS. Affordability and availability of off-patent drugs
in the United States-the case for importing from abroad: observational study. BMJ. 2018;360:k831.

4.

FDA. 2018 Office of Generic Drugs (OGD) Annual Report. 2018;
https://www.fda.gov/downloads/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/Generi
cDrugs/UCM631997.pdf. Accessed April 10th, 2019.

5.

FDA. First Generic Drug Approvals.
https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiolo
gicapprovalreports/andagenericdrugapprovals/default.htm. Accessed April 10th, 2019.

6.

Dave CV, Hartzema A, Kesselheim AS. Prices of Generic Drugs Associated with Numbers of
Manufacturers. N Engl J Med. 2017;377(26):2597-2598.

7.

Dave CV, Kesselheim AS, Fox ER, Qiu P, Hartzema A. High Generic Drug Prices and Market
Competition: A Retrospective Cohort Study. Ann Intern Med. 2017;167(3):145-151.

8.

Patel JM, Fox ER, Zocchi M, Lee Z-E, Mazer-Amirshahi M. Trends in United States Drug Shortages for
Medications Used in Gastroenterology. Medicine Access @ Point of Care. 2017;1:maapoc.0000012.

9.

Gupta R, Kesselheim AS, Downing N, Greene J, Ross JS. Generic Drug Approvals Since the 1984 HatchWaxman Act. JAMA Intern Med. 2016;176(9):1391-1393.

10.

FDA. FDA Tackles Drug Competition to Improve Patient Access. 2017;
https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm564725.htm. Accessed April 10th,
2019.

11.

FDA approves first generic drug under new pathway aimed at enhancing market competition for sole
source drugs [press release]. 2018.

12.

PEW. FDA Approves More Generic Drugs, but Competition Still Lags- FY 2012-17 program achieves
mixed results. 2019; https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2019/02/fdaapproves-more-generic-drugs-but-competition-still-lags. Accessed April 10, 2019

13.

FDA. Priority Review. https://www.fda.gov/ForPatients/Approvals/Fast/ucm405405.htm. Accessed April
10, 2019.

14.

FDA. Developing Products for Rare Diseases & Conditions.
https://www.fda.gov/forindustry/developingproductsforrarediseasesconditions/default.htm. Accessed April
10, 2019.

15.

FDA. Search Orphan Drug Designations and Approvals.
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm. Accessed April 10, 2019.

16.

WHO. Essential medicines. https://www.who.int/topics/essential_medicines/en/. Accessed April 10, 2019.

17.

WHO. ATC/DDD Index 2019. https://www.whocc.no/atc_ddd_index/. Accessed April 10, 2019.

18.

Carrier M, Kesselheim AS. The Daraprim Price Hike And A Role For Antitrust. 2015;
https://www.healthaffairs.org/do/10.1377/hblog20151021.051321/full/. Accessed April 10, 2019.

19.

Lowe D. The Case of Marathon Pharmaceuticals. In the Pipeline 2017;
https://blogs.sciencemag.org/pipeline/archives/2017/02/10/the-case-of-marathon-pharmaceuticals.
Accessed 2019, April 10.

20.

Sachs R. Rx Drug Policy At The FDA: Looking Back At Gottlieb And Ahead To Sharpless. 2019;
https://www.healthaffairs.org/do/10.1377/hblog20190402.434339/full/. Accessed April 10, 2019.

21.

Lupkin S, Hancock J. Trump Administration Salutes Parade Of Generic Drug Approvals, But Hundreds
Aren’t For Sale. 2019; https://khn.org/news/trump-administration-salutes-parade-of-generic-drugapprovals-but-hundreds-arent-for-sale/. Accessed April 10, 2019.

